Open access · CC-BY
via OpenAlex
Inflammatory Biomarkers in Heart Failure: Clinical Perspectives on hsCRP, IL-6 and Emerging Candidates
Berkan Kurt, Konstantin Rex, Martin Reugels, Christopher B. Fordyce, Marat Fudim, Abhinav Sharma, Martin Berger, Nikolaus Marx, Katharina Marx-Schütt, Florian Kahles
Current Heart Failure Reports · 2025 · ▲ 24 citations
Abstract
PURPOSE OF REVIEW: Heart failure (HF) remains a leading cause of morbidity and mortality worldwide. Increasing evidence highlights that systemic low-grade inflammation is a key pathophysiological driver of HF. This review seeks to examine the diagnostic and therapeutic relevance of inflammatory biomarkers - specifically interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) - and evaluate their potential for improving risk stratification and enabling personalized treatment approaches in HF. RECENT FINDINGS: IL-6 and hsCRP have emerged as important markers of residual inflammatory risk in HF. Elevated levels of these biomarkers are associated with increased risk of incident HF and adverse outcomes in established disease. While hsCRP is as a downstream marker of inflammation with no causal involvement, Mendelian randomization studies support a causal role of IL-6 signaling in the development of HF and coronary artery disease. Recent and ongoing clinical trials support the concept of targeting inflammatory pathways as a therapeutic strategy in selected HF populations. Inflammatory biomarkers, particularly IL-6 and hsCRP, are promising tools for advancing precision medicine in HF by improving individual risk assessment and guiding anti-inflammatory interventions. Further large-scale studies are needed to validate the integration of inflammatory biomarkers into clinical algorithms for HF and explore their potential role in future guideline recommendations and personalized prevention strategies.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1007/s11897-025-00710-3
- Canonical
- link ↗
- Fetched
- 2026-10-16 MST
Cite this
APA
Kurt, B., Rex, K., Reugels, M., Fordyce, C.B., Fudim, M., Sharma, A., Berger, M., Marx, N., Marx-Schütt, K., & Kahles, F. (2025). Inflammatory Biomarkers in Heart Failure: Clinical Perspectives on hsCRP, IL-6 and Emerging Candidates. <em>Current Heart Failure Reports</em>. https://doi.org/10.1007/s11897-025-00710-3
Vancouver
Kurt B, Rex K, Reugels M, Fordyce CB, Fudim M, Sharma A, et al. Inflammatory Biomarkers in Heart Failure: Clinical Perspectives on hsCRP, IL-6 and Emerging Candidates. Current Heart Failure Reports. 2025. doi:10.1007/s11897-025-00710-3.
BibTeX
@article{berkan2025Inflam,
title = {Inflammatory Biomarkers in Heart Failure: Clinical Perspectives on hsCRP, IL-6 and Emerging Candidates},
author = {Berkan Kurt and Konstantin Rex and Martin Reugels and Christopher B. Fordyce and Marat Fudim and Abhinav Sharma and Martin Berger and Nikolaus Marx and Katharina Marx-Schütt and Florian Kahles},
journal = {Current Heart Failure Reports},
year = {2025},
doi = {10.1007/s11897-025-00710-3},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
African Journal of Biomedical Research 2026
Open access · CC-BY
Inflammaging in Cardiovascular Disease: Emerging Mechanisms and Therapeutic Perspectives
Cardiology research and practice 2026
Open access · OA
Inflammation and the Heart: The Role of Traditional Factors.
Indian Journal of Pharmaceutical and Biological Research 2026
Open access · CC-BY
Effects of Anti-Inflammatory Pharmacotherapy on CRP and IL-6 Levels in Cardiovascular Disease: A Systematic Review
Circulation Research 2021
Open access · OA
Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
Pakistan Journal of Medical and Health Sciences 2024
Open access · CC-BY
Association of Serum Inflammatory Biomarkers (CRP, IL-6, TNF-α) with Ocular Complications and Severity of Chronic Rhinosinusitis in Diabetic and Non-Diabetic Patients
The Clinician 2021
Open access · CC-BY